Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Bamlanivimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
Bamlanivimab showed no clear difference in serious adverse events compared with placebo (low certainty).
Bamlanivimab/etesevimab may leads to lower mortality by day 30 compared with placebo (low certainty).
Summary of findings table ‐ NB‐UVB may leads to higher patient‐reported changes in symptoms compared with placebo (low certainty).
Summary of findings table ‐ NB‐UVB may leads to higher investigator Global Assessment (short‐term) compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).
Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).
Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).
The review found no eligible studies for this question.
Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).
It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).
It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).
Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).